Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cabozantinib plus atezolizumab vs sorafenib in advanced hepatocellular carcinoma
2018-003354-24Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cabozantinib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Exelixis, Inc. Primary endpoint: Duration of progression-free survival (PFS) for cabozantinib + atezolizumab vs sorafenib. Started Dec 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-003354-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003354-24.